Fig. 6: Drug testing methods for mPEOs in the USA300 infection model.
From: Use of mouse primary epidermal organoids for USA300 infection modeling and drug screening
A Overview of the three methods protocol steps (created with BioRender.com). The viability of infected mPEOs after treatment with DMSO, 12.8 μg/mL methicillin, 1.6 μg/mL and 3.2 μg/mL vancomycin was analyzed using a CellTiter-Lumi™ ATP assay. B Method A (n = 6, Ctrl group: 89119.28 ± 33928.97; Infection group: 20019.28 ± 18394.53; DMSO group: 4806.33 ± 1301.42; Met 12.8 μg/mL group: 21418.17 ± 9640.48; VA 1.6 μg/mL group: 8560.96 ± 8868.99; VA 3.2 μg/mL group: 37237.76 ± 39975.97). C method B (n = 6, Ctrl group: 137746.08 ± 39574.03; Infection group: 34833.32 ± 7176.01; DMSO group: 35910.03 ± 6193.07; Met 12.8 μg/mL group: 45786.43 ± 7628.59; VA 1.6 μg/mL group: 73176.32 ± 31063.43; VA 3.2 μg/mL group: 117408.70 ± 38819.92). D method C (n = 5, Ctrl group: 111847.12 ± 31074.82; Infection group: 10614.81 ± 633.50; DMSO group: 11657.73 ± 2164.49; Met 12.8 μg/mL group: 9753.12 ± 2082.89; VA 1.6 μg/mL group: 13274.31 ± 3204.52; VA 3.2 μg/mL group: 12869.72 ± 3419.86). E Fluorescent staining of mPEOs labeled with Calcein AM and Hoechst after treatment with DMSO, 12.8 μg/mL methicillin, 1.6 μg/mL and 3.2 μg/mL vancomycin (scale bars, 200 μm). F Immunofluorescence staining analysis of Staphylococcus aureus-specific biomarkers in infected mPEOs after treatment with DMSO, 12.8 μg/mL methicillin, 1.6 μg/mL or 3.2 μg/mL vancomycin (scale bars, 200 μm).
